| Document |
Document Title |
|
WO/2020/111178A1 |
An alcohol compound represented by formula [A] is provided. (In formula [A], R43 and R44 each independently represent an alkyl group having 1-27 carbon atoms and R45 represents a hydrogen atom or an alkyl group having 1-25 carbon atoms, ...
|
|
WO/2020/109613A1 |
The invention relates to specific quaternary amidoamine detergents, the process to make them, and their use. The quaternary amidoamine detergents are obtainable by reacting a multifunctional acid with an amino amine, followed by quaterni...
|
|
WO/2020/110615A1 |
Provided is a raw material feeder that can be operated stably and continuously over a long period, that supplies a raw material to a plurality of evaporation tubes in a falling film evaporator at a steady raw material distribution thereb...
|
|
WO/2020/110614A1 |
Provided is a method for producing N-vinylcarboxylic amide capable of suppressing blockage problems of a pyrolysis reactor caused by resins and also capable of operating stably and continuously over an extended period of time. A method f...
|
|
WO/2020/109638A1 |
The present invention relates to a multivariant metal–organic hybrid network formed by two different metals (M1 and M2) with at least two different oxamide ligands derived from at least two amino acids. The invention also relates to th...
|
|
WO/2020/103859A1 |
The invention provides amides that inhibit cellular necrosis including corresponding sulfonamides, prodrugs and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositi...
|
|
WO/2020/106780A1 |
Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene car...
|
|
WO/2020/102901A1 |
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...
|
|
WO/2020/101543A1 |
The invention relates to the field of medicinal chemistry and can be used in medicine as anti-inflammatory, neuroprotective agents, and also as cytostatic agents for use in oncology, by means of the use of derivatives of non-steroidal an...
|
|
WO/2020/093159A1 |
The present application relates to methods and compositions for preventing or treating influenza virus infections. In particular, the present application relates to the use of one or more broadly-neutralizing antibodies (bNAbs) in combin...
|
|
WO/2020/093949A1 |
The present invention relates to the field of high-carbon chain alkane diamine preparation, and disclosed thereby are a high-carbon chain alkane diamine, a preparation method therefor and an application thereof. The preparation method fo...
|
|
WO/2020/097389A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction betw...
|
|
WO/2020/089850A1 |
The present invention describes pharmaceutical compositions comprising compounds that have the formula and formula (compounds D14 and C22 respectively) that specifically inhibit the KRas4B- PDE6δ interaction, making them useful for the ...
|
|
WO/2020/092947A1 |
The present disclosure relates to novel compounds and methods of killing or inhibiting the growth of bacteria. In some embodiments, a method of killing or inhibiting the growth of bacteria is provided. The method comprises administering ...
|
|
WO/2020/092401A1 |
The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processe...
|
|
WO/2020/089326A1 |
The invention relates to a process for preparing fatty acid chlorides. In a subsequent step, the fatty acid chlorides can be used to prepare N-acyl amino acid salts. The process comprises the formation of a fatty acid chloride in an amin...
|
|
WO/2020/092383A1 |
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processe...
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/080495A1 |
The purpose of the present invention is to provide: a carboxylic acid-type lipid which can promote adhesion and coagulation of platelets without carrying a protein or peptide (e.g., GPIb or H12) which is involved in adhesion or coagulati...
|
|
WO/2020/080979A1 |
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...
|
|
WO/2020/073962A1 |
Provided is a metal complex as represented by formula I. The metal complex may be used as a catalyst for asymmetric catalytic hydrogenation, is capable of efficiently catalyzing and synthesizing a series of chiral β-aryl amides having h...
|
|
WO/2020/074964A1 |
The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative ther...
|
|
WO/2020/065321A1 |
A composition for forming an image on or within a substrate, the composition comprising: (a) an activatable component capable of transitioning from a non-coloured state to a coloured state, the transition being effected by the applicatio...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/061291A1 |
This invention provides methods for treating prostate cancer and benign prostatic hyperplasia. Each method comprises introducing biodegradable microspheres into one or more of a subject's prostate arteries, wherein the microspheres (i) h...
|
|
WO/2020/054226A1 |
A thermal base generator is represented by formula (N1). This photosensitive resin composition contains the thermal base generator and a precursor of a heterocycle-containing polymer. In formula (N1), RN1 and RN2 each independently repre...
|
|
WO/2020/052179A1 |
Provided is a preparation process for an amantadine nitrate derivative. The preparation process comprises preparing the amantadine nitrate derivative from substituted or unsubstituted adamantane used as a raw material by means of the fol...
|
|
WO/2020/051099A1 |
The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as...
|
|
WO/2020/047668A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...
|
|
WO/2020/047651A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer ...
|
|
WO/2020/047168A1 |
The present invention is directed towards new chemical entities winch primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, pa...
|
|
WO/2020/047399A1 |
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions t...
|
|
WO/2020/040049A1 |
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-2.0 parts by mass with respect to 100 parts by...
|
|
WO/2020/040315A1 |
A method for stabilizing a sanshool compound is provided. The method for stabilizing a sanshool compound comprises a mixing step in which the sanshool compound is mixed with an antioxidant in a liquid, the liquid comprising water and/or ...
|
|
WO/2020/041301A1 |
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the ...
|
|
WO/2020/040048A1 |
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-0.2 parts by mass with respect to 100 parts by...
|
|
WO/2020/040050A1 |
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. The composition according to the present invention includes a compound (A) represent...
|
|
WO/2020/040045A1 |
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. This composition includes a compound (A) represented by general formula (1), and a c...
|
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/034292A1 |
The present invention relates to the field of oil and gas field production increase transformations. Disclosed is a recyclable clean fracturing fluid thickening agent, a preparation method for same, a recycling method therefor, and a hig...
|
|
WO/2020/030931A1 |
The invention relates to a method of functionalising a diacetylene compound of formula (II) to form a diacetylene compound of formula (I): wherein x is from 1 to 20; Q is selected from an amide having the formula (IV) and an ester having...
|
|
WO/2020/025787A1 |
The invention relates to a process for the preparation of organo-iodinated compounds as well as the preparation intermediates thereof. More specifically, the invention relates to a process for the preparation of organo-iodinated compound...
|
|
WO/2020/020789A1 |
The invention relates to pharmaceutical dosage forms, which can be administered orally and have a modified release and contain sodium (3S)-3-(4-chloro-3-phenyl-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4
-trifluoro-3-methylbutanoyl]amino}phenyl)-...
|
|
WO/2020/020901A1 |
A method of forming a stable non-coloured or coloured state of a diacetylene compound having non-coloured, first coloured and second coloured states, the diacetylene compound being capable of transitioning from the non-coloured state to ...
|
|
WO/2020/020698A1 |
The invention relates to a process for preparing N-methyl(meth)acrylamide and to the uses thereof.
|
|
WO/2020/017557A1 |
Provided are: a compound suitable for imaging an intracerebral TRPV1 receptor; and a use thereof. A compound or a salt thereof represented by formula (I) is used. [In formula (1), R1 is a hydrogen or a random organic group; R2 is an orga...
|
|
WO/2020/009016A1 |
The present invention provides a method for producing an organic compound in which functional groups are reacted with each other without the use of a solvent. The present invention pertains to a method for producing an organic compound c...
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/001298A1 |
Provided in the present invention are a 4-(p-trifluoromethylbenzyl)-3-floro-1,2,4 triphenylamine derivative, a pharmaceutical composition of same, and uses thereof. The chemical formula of the derivative is as represented by formula I, w...
|
|
WO/2020/006367A1 |
The invention provides methods and compositions for use in the prevention and treatment of antipsychotic medication-induced metabolic syndrome (MetS) and diseases and conditions related to MetS.
|
